266306-18-7

Usage

Uses

Used in Pharmaceutical Synthesis:
N-Boc-4-bromo-L-phenylalanine methyl ester is used as a building block for the synthesis of various pharmaceuticals. Its unique structure allows for the incorporation of specific functional groups, such as the bromo and methyl ester groups, which can be further modified to create new and innovative drugs.
Used in Peptide Synthesis:
N-Boc-4-bromo-L-phenylalanine methyl ester is used as an amino acid precursor in the synthesis of peptides. The N-Boc group protects the amino group during peptide synthesis, preventing unwanted side reactions and allowing for the selective incorporation of the desired amino acid into the peptide sequence.
Used in Chemical Synthesis:
N-Boc-4-bromo-L-phenylalanine methyl ester is used as a versatile intermediate in chemical synthesis. The bromo group can be used in cross-coupling reactions to introduce various functional groups, while the methyl ester group provides increased stability and solubility in organic solvents.
Used in Biochemical Research:
N-Boc-4-bromo-L-phenylalanine methyl ester is used as a research tool in biochemical studies. Its unique structure allows for the investigation of various biological processes, such as enzyme activity, protein-protein interactions, and signal transduction pathways.
Used in Drug Delivery Systems:
N-Boc-4-bromo-L-phenylalanine methyl ester can be used in the development of drug delivery systems, where its unique chemical properties can be exploited to improve the stability, solubility, and bioavailability of therapeutic agents.
Used in the Development of Novel Compounds:
N-Boc-4-bromo-L-phenylalanine methyl ester can be used as a starting material for the development of novel compounds with potential applications in various industries, such as agriculture, materials science, and environmental science.

Upstream product

• 589-87-7 1,4-bromoiodobenzene 
• 93267-04-0 N-(tert-butoxycarbonyl)-L-3-iodoalanine methyl ester 
• 62129-39-9 4-bromo-N-{[(1,1-dimethylethyl)oxy]carbonyl}-L-phenylalanine 
• 74-88-4 methyl iodide 
• 24250-84-8 H-p-BrPhe-OH 
• 24424-99-5 di-tert-butyl dicarbonate 
• 99359-32-7 (S)-2-amino-3-(4-bromophenyl)propionic acid methyl ester hydrochloride 
• 67-56-1 methanol 

Downstream Products

• 959992-97-3 methyl N-(tert-butoxycarbonyl)-4-[3-(1,8-naphthyridin-2-yl)prop-1-en-1-yl]-L-phenylalaninate 
• 959992-98-4 methyl N-(tert-butoxycarbonyl)-4-[1-methyl-2-(1,8-naphthyridin-2-yl)ethenyl]-L-phenylalaninate 
• 1006587-33-2 1-{(2S)-2-[(benzyloxycarbonyl)amino]-2-[(tert-butoxycarbonyl)]ethyl}-4-{(2S)-2-[(tert-butoxycarbonyl)amino]-2-(methoxycarbonyl)ethyl}-benzene 
• 1398718-23-4 C₉H₉BrN₂ 
• 1398717-93-5 (S)-D₆-1-amino-N-(1-cyano-2-(4'-((4-methyl-piperazin-1-yl)methyl)biphenyl-4-yl)ethyl)cyclohexanecarboxamide 
• 1398717-97-9 (R)-1-amino-N-(1-cyano-2-(4'-((4-propylpiperazin-1-yl)methyl)biphenyl-4-yl)ethyl)cyclohexanecarboxamide 
• 1398717-99-1 (R)-1-amino-N-(1-cyano-2-(4'-((4-cyclopropyl-piperazin-1-yl)methyl)biphenyl-4-yl)ethyl)cyclohexanecarboxamide 
• 1398718-01-8 (R)-1-amino-N-(1-cyano-2-(4'-((4-(cyanomethyl)piperazin-1-yl)methyl)biphenyl-4-yl)ethyl)cyclohexanecarboxamide 
• 869569-99-3 tert-butyl (S)-(1-amino-3-(4-bromophenyl)-1-oxopropan-2-yl)carbamate 
• 869570-00-3 tert-butyl (S)-[2-(4-bromophenyl)-1-cyanoethyl]carbamate 
• 1398718-36-9 (S)-(9H-fluoren-9-yl)methyl 1-(1-cyano-2-(4'-((4-methylpiperazin-1-yl)methyl)-biphenyl-4-yl)ethylcarbamoyl)cyclohexylcarbamate 
• 1398718-42-7 (S)-(9H-fluoren-9-yl)methyl 1-(1-cyano-2-(4'-(4-methylpiperazin-1-ylsulfonyl)-biphenyl-4-yl)ethylcarbamoyl)cyclohexylcarbamate 
• 1398717-81-1 (S)-1-amino-N-(1-cyano-2-(4'-((4-methylpiperazin-1-yl)methyl)biphenyl-4-yl)ethyl)cyclohexanecarboxamide 
• 1398718-47-2 (9H-fluoren-9-yl)methyl (S)-2-((S)-1-cyano-2-(4'-(4-methylpiperazin-1-ylsulfon-yl)biphenyl-4-yl)ethylcarbamoyl)-1,2,3,4-tetrahydronaphthalen-2-ylcarbamate 

Relevant academic research and scientific papers

Studies Toward the Total Synthesis and Stereochemical Assignment of Microspinosamide

Efforts toward the total synthesis and stereochemical assignment of the cyclic depsipeptide natural product microspinosamide are described. A single diastereoisomer was targeted corresponding to the predicted structure of the natural product incorporating a (2S, 3R)-β-hydroxy-p-bromophenylalanine residue. Assembly was achieved through the initial synthesis of a cyclic depsipeptide and a linear peptide thioester fragment by solid-phase peptide synthesis, followed by fusion of the two fragments through a native chemical ligation-oxidation protocol. Extensive spectroscopic analysis showed structural differences to the isolated natural product, suggesting that a diastereoisomer of microspinosamide had been synthesised. This work lays the foundation for the future synthesis of the correct diastereoisomer.

ANTIMICROBIAL COMPOUNDS AND METHODS

The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.

Synthesis and evaluation of photo-activatable β-diarylsydnone-L-alanines for fluorogenic photo-click cyclization of peptides

Herein, we design and synthesize a series of photoactivatable β-diarylsydnone-l-alanines (DASAs), which have excellent photo-reactivity with high fluorescence turn-on toward alkenes in a biocompatible environment. The environmental sensing properties of t

INTEGRIN ANTAGONISTS

The present disclosure provides therapeutic agents including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such therapeutic agents. Methods of using the therapeutic agents are also provided.

Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains

As an important member of anti-apoptotic Bcl-2 protein, myeloid cell leukemia sequence 1 (Mcl-1) protein is an attractive target for cancer therapy. In this study, a new series of pyrrolidine derivatives as Mcl-1 inhibitors were developed by mainly modifying the amino acid side chain of compound 1. Among them, compound 18 (Ki= 0.077 μM) exhibited better potent inhibitory activities towards Mcl-1 protein compared to positive control Gossypol (Ki= 0.18 μM). In addition, compound 40 possessed good antiproliferative activities against PC-3 cells (Ki= 8.45 μM), which was the same as positive control Gossypol (Ki= 7.54 μM).

PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS

The invention relates to compounds of Formula (I) and its use as a selective dipeptidyl peptidase I inhibitor, as well as pharmaceutical compositions comprising said compounds, and methods of treatment involving said compounds.

N-SUBSTITUTED 3,3'-(BIPHENYL-4,4'-DIYL)BIS-2-AMINOPROPANENITRILES AS DPPI INHIBITORS

The invention relates to a compound of Formula (I) and its use as a selective dipeptidyl peptidase I inhibitor, as well as pharmaceutical compositions comprising said compound, and methods of treatment involving said compounds.

PEPTIDYL NITRILCOMPOUNDS AS PEPTIDASE INHIBITORS

The invention relates to compounds of Formula (II) and their use in theraphy as peptidase inhibitors.

Negishi cross-coupling reactions of α-amino acid-derived organozinc reagents and aromatic bromides

The Negishi cross-coupling reaction of organozinc iodides derived from α-amino acids with aromatic bromides to give substituted phenylalanine derivatives is described, using either Pd(OAc)2 or Pd2(dba)3 in combination with P(o-Tol)3 as catalyst in DMF at 50 °C. Similar results are obtained using Pd[PtBu3]2 as catalyst. The difference in reactivity displayed between aryl iodides and bromides (ArI>ArBr) has been utilised in a short synthesis of an unsymmetrical, orthogonally protected para-phenylene bis-alanine derivative.

CYCLIC PEPTIDE ANTITUMOR AGENTS

Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.